<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0012122'>anterior uveitis</z:hpo> may be treated with topical therapy alone but patients with <z:hpo ids='HP_0012123'>posterior uveitis</z:hpo> and those with sight threatening complications of <z:hpo ids='HP_0012122'>anterior uveitis</z:hpo> usually require systemic treatment especially if the disease is bilateral </plain></SENT>
<SENT sid="1" pm="."><plain>The mainstay of treatment is <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and additional <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> such as cyclosporin and <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> are used when necessary </plain></SENT>
<SENT sid="2" pm="."><plain>There remains a significant cohort of patients in whom this therapy is either not tolerated or is ineffective </plain></SENT>
<SENT sid="3" pm="."><plain>The use of the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) antibodies has been very successful in controlling other immune-mediated disorders such as <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> and has subsequently been extended to use in other arthritidies and other disorders such as <z:hpo ids='HP_0003765'>psoriasis</z:hpo> and <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>TNF is known to play a key role in <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> as shown by animal studies and its detection in the ocular fluids of <z:e sem="disease" ids="C0155169" disease_type="Disease or Syndrome" abbrv="">inflamed eyes</z:e> in man </plain></SENT>
<SENT sid="5" pm="."><plain>In some disorders <z:hpo ids='HP_0000001'>all</z:hpo> types of anti-TNF antibodies have similar efficacy but that does not appear to be the case with <z:hpo ids='HP_0000554'>uveitis</z:hpo> where infliximab is at present looking to be more effective than etanercept </plain></SENT>
<SENT sid="6" pm="."><plain>The data on the use of anti-TNF drugs in <z:hpo ids='HP_0000554'>uveitis</z:hpo> is presented together with new data on its role as a steroid sparing agent </plain></SENT>
</text></document>